The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004

Table 5 Pneumococcal vaccination status and relative risk (RR) of mortality in patients aged 65 years and over

Group	Total no. in group	% Died	RR Mortality (95% CI) Crude	RR (95% CI) adjusted for age group and gender	NNV^§ to prevent 1 death
All age 65+ years
No vaccine	82	32.9	1.00	1.00	14,810
Vaccine	63	28.6	0.86 (0.47, 1.56)	0.89 (0.49, 1.63)
Age group (years)
65–74
No vaccine	27	22.2	1.00	-	39,172
Vaccine	25	16.0	0.71 (0.20, 2.51)
75+
No vaccine	55	38.2	1.00	-	8,122
Vaccine	38	36.8	0.96 (0.49, 1.89)
Gender
Males
No vaccine	31	32.3	1.00	-
Vaccine	34	29.4	0.90 (0.38, 2.17)
Females
No vaccine	51	33.3	1.00	-
Vaccine	29	27.6	0.81 (0.35, 1.89)

^§ NNV: Number needed to vaccinate to prevent 1 death. Note: since the reduction in mortality risk was not significant, these are hypothetical estimates included only for comparison purposes.

ISSN: 1471-2334